The Centers For Women's Health In Stamford CT Pioneers Breast Cancer Risk Assessment

STAMFORD, Conn., March 18, 2013 (GLOBE NEWSWIRE) -- Dr. Joel Evans, Founder and Director of The Center for Women's Health, is one of the first physicians in the nation to make the BREVAGen™ predictive risk test available to his patients. Clinically validated, BREVAGen is the latest advance in assessing a woman's unique risk of developing non-familial or sporadic breast cancer. "At The Center for Women's Health, we believe that optimal healthcare combines the best of modern medicine with the wisdom of traditional healing," said Dr. Joel Evans, Founder and Director of The Center for Women's Health. "BREVAGen enables us to accurately assess a woman's overall risk of developing breast cancer so we can create appropriate plans to minimize her risk, including more informed decisions about hormone replacement therapies, breast monitoring and surveillance schedules, and lifestyle choices." BREVAGen is a clinically validated predictive risk test that more accurately identifies a woman's unique risk of developing sporadic, estrogen-positive breast cancer. BREVAGen examines a woman's clinical risk factors, such as their lifetime exposure to estrogen, combined with scientifically validated markers to determine each patient's personalized five-year and lifetime risk of developing breast cancer.1 BREVAGen is supplied by Phenogen Sciences, a subsidiary of Genetic Technologies Limited (Nasdaq:GENE). For more information about The Center for Women's Health use of BREVAGen, contact Mary Kate DiSalvo at (203) 321-0200. How BREVAGen Works
desc

The BREVAGen predictive risk test is administered in a physician's office using a simple, non-invasive "oral-swab". Following analysis in a CLIA-certified laboratory, physicians receive a comprehensive genetic risk prediction report to review with the patient. The patient's risk of breast cancer is calculated by combining their relative risk score from seven genetic markers, called SNPs (single nucleotide polymorphisms), with factors that comprise the patient's clinical and reproductive history including current age, age at menarche, age at live first birth and race/ethnicity. The BREVAGen test provides five-year and lifetime predictive risk assessments to more accurately evaluate the patient's risk for developing sporadic breast cancer, regardless of family history or previous indeterminate test results. Clinically Validated

BREVAGen was proven superior in determining breast cancer risk compared to Gail score alone.1 Utilizing data from the U.S. Women's Health Initiative (WHI) Clinical Trial, 3,300 women underwent breast cancer assessment utilizing the BREVAGen test. Of those 3,300 women, 1,664 were diagnosed with breast cancer and 1,636 were in the breast cancer-free control group. BREVAGen test results support current American Cancer Society (ACS) [ www.cancer.org], American Society of Clinical Oncology (ASCO) [ www.asco.org] and The National Comprehensive Care Network (NCCN) [ www.nccn.org] guidelines for prevention and early detection of breast cancer.2, 3 About The Center for Women's Health

The Center for Women's Health is a state-of-the-art women's health center, combining the best of modern medicine with the wisdom of traditional healing. Patients at the Center are offered the most up to date leading edge medical evaluation and treatment as well as scientifically studied, natural holistic options individually designed to improve their health and prevent disease. For additional information about The Center for Women's Health, please visit www.CenterForWomensHealth.com . About Phenogen Sciences

Phenogen Sciences, the U.S. subsidiary of Australia-based Genetic Technologies Limited, is a pioneer in personalized healthcare. Phenogen offers novel predictive testing and assessment tools that help physicians proactively manage women's health risks.

If you liked this article you might like

5 Stocks Under $10 Set to Soar

5 Stocks Ready for Breakouts

Genetic Technologies (GENE) Rises Today as More Centers Adopt Breast Cancer Test

Stalking an Entry in RetailMeNot

Stalking an Entry in RetailMeNot

Why Genetic Technologies (GENE) Stock Is Spiking Today